Literature DB >> 23977446

Krüppel-like factor 8 promotes tumorigenic mammary stem cell induction by targeting miR-146a.

Xianhui Wang1, Heng Lu, Tianshu Li, Lin Yu, Gang Liu, Xu Peng, Jihe Zhao.   

Abstract

The properties of stem cells can be induced during the epithelial to mesenchymal transition (EMT). The responsible molecular mechanisms, however, remain largely undefined. Here we report the identification of the microRNA-146a (miR-146a) as a common target of Krüppel-like factor 8 (KLF8) and TGF-β, both of which are known EMT-inducers. Upon KLF8 overexpression or TGF-β treatment, a significant portion of the MCF-10A cells gained stem cell traits as demonstrated by an increased expression of CD44(high)/CD24low, activity of aldehyde dehydrogenase (ALDH), mammosphere formation and chemoresistance. Along with this change, the expression of miR-146a was highly upregulated in the cells. Importantly, we found that miR-146a was aberrantly co-overexpressed with KLF8 in a panel of invasive human breast cancer cell lines. Ectopic expression of KLF8 failed to induce the stem cell traits in the MCF-10A cells if the cells were pre-treated with miR-146a inhibitor, whereas overexpression of miR-146a in the MCF-10A cells alone was sufficient to induce the stem cell traits. Co-staining and luciferase reporter analyses indicated that miR-146a targets the 3'-UTR of the Notch signaling inhibitor NUMB for translational inhibition. Overexpression of KLF8 dramatically potentiated the tumorigenecity of MCF-10A cells expressing the H-Ras oncogene, which was accompanied by a loss of NUMB expression in the tumors. Taken together, this study identifies a novel role and mechanism for KLF8 in inducing pro-tumorigenic mammary stem cells via miR-146a potentially by activating Notch signaling. This mechanism could be exploited as a therapeutic target against drug resistance of breast cancer.

Entities:  

Keywords:  EMT; KLF8; mammary stem cells; miR-146a; tumorigenesis

Year:  2013        PMID: 23977446      PMCID: PMC3744016     

Source DB:  PubMed          Journal:  Am J Cancer Res        ISSN: 2156-6976            Impact factor:   6.166


  73 in total

1.  Krüppel-like factor 8 induces epithelial to mesenchymal transition and epithelial cell invasion.

Authors:  Xianhui Wang; Mingzhe Zheng; Gang Liu; Weiya Xia; Paula J McKeown-Longo; Mien-Chie Hung; Jihe Zhao
Journal:  Cancer Res       Date:  2007-08-01       Impact factor: 12.701

2.  Orally bioavailable small-molecule inhibitor of transcription factor Stat3 regresses human breast and lung cancer xenografts.

Authors:  Xiaolei Zhang; Peibin Yue; Brent D G Page; Tianshu Li; Wei Zhao; Andrew T Namanja; David Paladino; Jihe Zhao; Yuan Chen; Patrick T Gunning; James Turkson
Journal:  Proc Natl Acad Sci U S A       Date:  2012-05-23       Impact factor: 11.205

3.  NF-kappaB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses.

Authors:  Konstantin D Taganov; Mark P Boldin; Kuang-Jung Chang; David Baltimore
Journal:  Proc Natl Acad Sci U S A       Date:  2006-08-02       Impact factor: 11.205

4.  Lentivirus-delivered Krüppel-like factor 8 small interfering RNA inhibits gastric cancer cell growth in vitro and in vivo.

Authors:  Lili Liu; Na Liu; Min Xu; Yi Liu; Jie Min; Hailin Pang; Ning Zhang; Hongbo Zhang; Helong Zhang
Journal:  Tumour Biol       Date:  2011-11-15

Review 5.  MicroRNAs, cancer and cancer stem cells.

Authors:  Amy L Zimmerman; Shiyong Wu
Journal:  Cancer Lett       Date:  2010-10-20       Impact factor: 8.679

Review 6.  The emerging role of miR-200 family of microRNAs in epithelial-mesenchymal transition and cancer metastasis.

Authors:  Manav Korpal; Yibin Kang
Journal:  RNA Biol       Date:  2008 Jul-Sep       Impact factor: 4.652

7.  The properties of tumor-initiating cells from a hepatocellular carcinoma patient's primary and recurrent tumor.

Authors:  Xiao-Lan Xu; Bao-Cai Xing; Hai-Bo Han; Wei Zhao; Mei-Hao Hu; Zuo-Liang Xu; Ji-You Li; Yong Xie; Jun Gu; Yu Wang; Zhi-Qian Zhang
Journal:  Carcinogenesis       Date:  2009-11-06       Impact factor: 4.944

8.  Up-regulation of miR-200 and let-7 by natural agents leads to the reversal of epithelial-to-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells.

Authors:  Yiwei Li; Timothy G VandenBoom; Dejuan Kong; Zhiwei Wang; Shadan Ali; Philip A Philip; Fazlul H Sarkar
Journal:  Cancer Res       Date:  2009-08-04       Impact factor: 12.701

Review 9.  Roles of microRNAs in cancer stem cells.

Authors:  Nanjiang Zhou; Yin-Yuan Mo
Journal:  Front Biosci (Schol Ed)       Date:  2012-01-01

10.  Direct targeting of Sec23a by miR-200s influences cancer cell secretome and promotes metastatic colonization.

Authors:  Manav Korpal; Brian J Ell; Francesca M Buffa; Toni Ibrahim; Mario A Blanco; Toni Celià-Terrassa; Laura Mercatali; Zia Khan; Hani Goodarzi; Yuling Hua; Yong Wei; Guohong Hu; Benjamin A Garcia; Jiannis Ragoussis; Dino Amadori; Adrian L Harris; Yibin Kang
Journal:  Nat Med       Date:  2011-08-07       Impact factor: 53.440

View more
  21 in total

1.  miR-21 and miR-375 microRNAs as candidate diagnostic biomarkers in squamous cell carcinoma of the larynx: association with patient survival.

Authors:  An Hu; Jing-Juan Huang; Wei-Hua Xu; Xiao-Jie Jin; Ji-Ping Li; Yuan-Jia Tang; Xin-Fang Huang; Hui-Juan Cui; Guang-Bin Sun
Journal:  Am J Transl Res       Date:  2014-10-11       Impact factor: 4.060

2.  MiR-21/miR-375 ratio is an independent prognostic factor in patients with laryngeal squamous cell carcinoma.

Authors:  An Hu; Jing-Juan Huang; Wei-Hua Xu; Xiao-Jie Jin; Ji-Ping Li; Yuan-Jia Tang; Xin-Fang Huang; Hui-Juan Cui; Guang-Bin Sun; Rui-Lin Li; Jun-Li Duan
Journal:  Am J Cancer Res       Date:  2015-04-15       Impact factor: 6.166

3.  MicroRNAs, a subpopulation of regulators, are involved in breast cancer progression through regulating breast cancer stem cells.

Authors:  Xuemei Fan; Wei Chen; Ziyi Fu; Lihua Zeng; Yongmei Yin; Hongyan Yuan
Journal:  Oncol Lett       Date:  2017-09-01       Impact factor: 2.967

Review 4.  Cancer stem cells and chemoresistance: The smartest survives the raid.

Authors:  Jihe Zhao
Journal:  Pharmacol Ther       Date:  2016-02-17       Impact factor: 12.310

5.  FOXP3 Controls an miR-146/NF-κB Negative Feedback Loop That Inhibits Apoptosis in Breast Cancer Cells.

Authors:  Runhua Liu; Cong Liu; Dongquan Chen; Wei-Hsiung Yang; Xiuping Liu; Chang-Gong Liu; Courtney M Dugas; Fei Tang; Pan Zheng; Yang Liu; Lizhong Wang
Journal:  Cancer Res       Date:  2015-02-23       Impact factor: 12.701

Review 6.  Role of Krüppel-like factors in cancer stem cells.

Authors:  Yueling Zhang; Jin Hao; Yingcheng Zheng; Dian Jing; Yu Shen; Jun Wang; Zhihe Zhao
Journal:  J Physiol Biochem       Date:  2015-01-24       Impact factor: 4.158

7.  Role of krüppel-like factor 8 for therapeutic drug-resistant multi-organ metastasis of breast cancer.

Authors:  Jie Hao; Heng Lu; Debarati Mukherjee; Lin Yu; Jihe Zhao
Journal:  Am J Cancer Res       Date:  2021-05-15       Impact factor: 6.166

8.  Peroxisome proliferator-activated receptor-γ agonist inhibits collagen synthesis in human keloid fibroblasts by suppression of early growth response-1 expression through upregulation of miR-543 expression.

Authors:  Hua-Yu Zhu; Wen-Dong Bai; Hong-Tao Wang; Song-Tao Xie; Ke Tao; Lin-Lin Su; Jia-Qi Liu; Xue-Kang Yang; Jun Li; Yun-Chuan Wang; Ting He; Jun-Tao Han; Da-Hai Hu
Journal:  Am J Cancer Res       Date:  2016-06-01       Impact factor: 6.166

9.  O-GlcNAc Transferase Regulates Cancer Stem-like Potential of Breast Cancer Cells.

Authors:  Neha M Akella; Giang Le Minh; Lorela Ciraku; Ayonika Mukherjee; Zachary A Bacigalupa; Dimpi Mukhopadhyay; Valerie L Sodi; Mauricio J Reginato
Journal:  Mol Cancer Res       Date:  2020-01-23       Impact factor: 5.852

Review 10.  MicroRNAs, a Promising Target for Breast Cancer Stem Cells.

Authors:  Plabon Kumar Das; Mst Ayesha Siddika; Saharia Yeasmin Asha; Suraiya Aktar; Md Abdur Rakib; Jahan Ara Khanam; Suja Pillai; Farhadul Islam
Journal:  Mol Diagn Ther       Date:  2020-02       Impact factor: 4.074

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.